Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein carbamylation is a nonenzymatic post-translational modification involving the covalent binding of isocyanic acid to proteins, primarily at N-terminal α-amino groups and lysine ε-amino groups, forming homocitrulline. This modification alters protein structure and function, contributing to aging and disease processes, notably in chronic kidney disease, atherosclerosis, and inflammatory conditions. Carbamylation serves as a biomarker for disease progression and can impact protein-protein interactions and cellular clearance mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Carbamylation.